BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 14616151)

  • 21. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.
    Richter JE; Peura D; Benjamin SB; Joelsson B; Whipple J
    Arch Intern Med; 2000 Jun; 160(12):1810-6. PubMed ID: 10871975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
    Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Adler J; Eklund S
    Aliment Pharmacol Ther; 2005 Nov; 22(9):803-11. PubMed ID: 16225489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid resolution of sleep disturbances related to frequent reflux: effect of esomeprazole 20 mg in two randomized, double-blind, controlled trials.
    Johnson DA; Le Moigne A; Hugo V; Nagy P
    Curr Med Res Opin; 2015 Feb; 31(2):243-50. PubMed ID: 25478944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pilot, Randomized, Blinded, Placebo-Controlled Trial Investigating the Correlation Between Acid Control and Heartburn Relief with 14 Days of Esomeprazole Treatment.
    Miner PB; Johnson DA; Katz PO; Li J; Gatoulis SC; Pollack C
    Adv Ther; 2018 Nov; 35(11):2024-2040. PubMed ID: 30255418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial.
    Johnson DA; Orr WC; Crawley JA; Traxler B; McCullough J; Brown KA; Roth T
    Am J Gastroenterol; 2005 Sep; 100(9):1914-22. PubMed ID: 16128933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances.
    Johnson D; Crawley JA; Hwang C; Brown K
    Aliment Pharmacol Ther; 2010 Jul; 32(2):182-90. PubMed ID: 20456306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of heartburn resolution and erosive esophagitis in patients with GERD.
    Orlando RC; Monyak JT; Silberg DG
    Curr Med Res Opin; 2009 Sep; 25(9):2091-102. PubMed ID: 19601705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study.
    Labenz J; Armstrong D; Zetterstrand S; Eklund S; Leodolter A
    Aliment Pharmacol Ther; 2009 May; 29(9):959-66. PubMed ID: 19222417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ranitidine 300 mg twice daily and 150 mg four-times daily are effective in healing erosive oesophagitis.
    Silver MT; Murdock RH; Morrill BB; Sue SO
    Aliment Pharmacol Ther; 1996 Jun; 10(3):373-80. PubMed ID: 8791966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 14-day regimen of esomeprazole 20 mg/day for frequent heartburn: durability of effects, symptomatic rebound, and treatment satisfaction.
    Peura D; Le Moigne A; Pollack C; Nagy P; Lind T
    Postgrad Med; 2016 Aug; 128(6):577-83. PubMed ID: 27331882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.
    Lee KJ; Son BK; Kim GH; Jung HK; Jung HY; Chung IK; Sung IK; Kim JI; Kim JH; Lee JS; Kwon JG; Park JH; Huh KC; Park KS; Park MI; Kim N; Lee OY; Jee SR; Lee SK; Youn SJ; Kim SK; Lee ST; Hong SJ; Choi SC; Kim TN; Youn YH; Park HJ; Kang MJ; Park CH; Kim BT; Youn S; Song GS; Rhee PL
    Aliment Pharmacol Ther; 2019 Apr; 49(7):864-872. PubMed ID: 30843245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study.
    Malfertheiner P; Lind T; Willich S; Vieth M; Jaspersen D; Labenz J; Meyer-Sabellek W; Junghard O; Stolte M
    Gut; 2005 Jun; 54(6):746-51. PubMed ID: 15888776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole.
    Armstrong D; Talley NJ; Lauritsen K; Moum B; Lind T; Tunturi-Hihnala H; Venables T; Green J; Bigard MA; Mössner J; Junghard O
    Aliment Pharmacol Ther; 2004 Aug; 20(4):413-21. PubMed ID: 15298635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients.
    Richter JE; Kahrilas PJ; Sontag SJ; Kovacs TO; Huang B; Pencyla JL
    Am J Gastroenterol; 2001 Nov; 96(11):3089-98. PubMed ID: 11721754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies.
    Kushner PR; Snoddy AM; Gilderman L; Peura DA
    Postgrad Med; 2009 Jul; 121(4):67-75. PubMed ID: 19641272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
    Metz DC; Howden CW; Perez MC; Larsen L; O'Neil J; Atkinson SN
    Aliment Pharmacol Ther; 2009 Apr; 29(7):742-54. PubMed ID: 19210298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
    Richter JE; Kahrilas PJ; Johanson J; Maton P; Breiter JR; Hwang C; Marino V; Hamelin B; Levine JG;
    Am J Gastroenterol; 2001 Mar; 96(3):656-65. PubMed ID: 11280530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months.
    Talley NJ; Lauritsen K; Tunturi-Hihnala H; Lind T; Moum B; Bang C; Schulz T; Omland TM; Delle M; Junghard O
    Aliment Pharmacol Ther; 2001 Mar; 15(3):347-54. PubMed ID: 11207509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis.
    Maton PN; Vakil NB; Levine JG; Hwang C; Skammer W; Lundborg P;
    Drug Saf; 2001; 24(8):625-35. PubMed ID: 11480494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.